Compare Stocks: KRRO, AURA, STTK, and BBOT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$7.11 -3.9%	$7.31	$4.73 ▼ $9.53	$737.34M	0.4	474,954 shs	195,453 shs
BBOT BridgeBio Oncology Therapeutics	$8.61 -1.5%	$8.61	$7.00 ▼ $14.87	$690.26M	0.35	354,489 shs	259,458 shs
KRRO Korro Bio	$12.52 -3.0%	$12.78	$5.20 ▼ $55.89	$184.42M	3.04	191,044 shs	20,920 shs
STTK Shattuck Labs	$6.88 -2.3%	$7.05	$0.97 ▼ $8.33	$690.48M	1.08	891,034 shs	283,064 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	0.00%	-5.13%	+5.56%	+2.92%	+18.21%
BBOT BridgeBio Oncology Therapeutics	0.00%	-3.74%	+8.03%	+2.22%	+873,999,900.00%
KRRO Korro Bio	0.00%	-2.05%	+24.49%	-0.15%	-44.06%
STTK Shattuck Labs	0.00%	-6.51%	-0.42%	+24.60%	+617.78%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$7.11 -3.9%	$7.31	$4.73 ▼ $9.53	$737.34M	0.4	474,954 shs	195,453 shs
BBOT BridgeBio Oncology Therapeutics	$8.61 -1.5%	$8.61	$7.00 ▼ $14.87	$690.26M	0.35	354,489 shs	259,458 shs
KRRO Korro Bio	$12.52 -3.0%	$12.78	$5.20 ▼ $55.89	$184.42M	3.04	191,044 shs	20,920 shs
STTK Shattuck Labs	$6.88 -2.3%	$7.05	$0.97 ▼ $8.33	$690.48M	1.08	891,034 shs	283,064 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	0.00%	-5.13%	+5.56%	+2.92%	+18.21%
BBOT BridgeBio Oncology Therapeutics	0.00%	-3.74%	+8.03%	+2.22%	+873,999,900.00%
KRRO Korro Bio	0.00%	-2.05%	+24.49%	-0.15%	-44.06%
STTK Shattuck Labs	0.00%	-6.51%	-0.42%	+24.60%	+617.78%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	2.33	Hold	$17.50	146.13% Upside
BBOT BridgeBio Oncology Therapeutics	2.75	Moderate Buy	$24.40	183.39% Upside
KRRO Korro Bio	2.92	Moderate Buy	$16.71	33.50% Upside
STTK Shattuck Labs	3.00	Buy	$12.78	85.72% Upside

Current Analyst Ratings Breakdown

Latest KRRO, AURA, STTK, and BBOT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	STTK Shattuck Labs	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/20/2026	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
8/14/2026	BBOT BridgeBio Oncology Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$27.00 ➝ $25.00
8/11/2026	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$24.00 ➝ $18.00
8/11/2026	STTK Shattuck Labs	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$18.00 ➝ $14.00
7/24/2026	STTK Shattuck Labs	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$10.00
7/20/2026	STTK Shattuck Labs	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$16.00
7/14/2026	AURA Aura Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	BBOT BridgeBio Oncology Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$2.16 per share	N/A
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	$5.14 per share	N/A
KRRO Korro Bio	$6.39M	28.86	N/A	N/A	$5.46 per share	2.29
STTK Shattuck Labs	$1M	690.48	N/A	N/A	$1.30 per share	5.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$106.19M	-$1.75	N/A	N/A	N/A	N/A	-73.18%	-62.00%	11/12/2026 (Estimated)
BBOT BridgeBio Oncology Therapeutics	-$134.04M	-$2.76	N/A	N/A	N/A	N/A	-46.90%	-42.17%	N/A
KRRO Korro Bio	-$117.26M	-$10.00	N/A	N/A	N/A	-1,834.48%	-114.26%	-68.57%	11/11/2026 (Estimated)
STTK Shattuck Labs	-$48.81M	-$0.51	N/A	N/A	N/A	N/A	-43.57%	-40.90%	11/10/2026 (Estimated)

Latest KRRO, AURA, STTK, and BBOT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	AURA Aura Biosciences	-$0.3750	-$0.48	-$0.1050	-$0.48	N/A	N/A
8/11/2026	Q2 2026	BBOT BridgeBio Oncology Therapeutics	N/A	-$705.20	N/A	-$705.20	N/A	N/A
8/11/2026	Q2 2026	STTK Shattuck Labs	-$0.1241	-$0.12	+$0.0041	-$0.12	N/A	N/A
8/6/2026	Q2 2026	KRRO Korro Bio	-$1.34	-$1.07	+$0.27	-$1.07	$0.21 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	16.82	16.82
BBOT BridgeBio Oncology Therapeutics	N/A	4.69	4.69
KRRO Korro Bio	N/A	9.55	9.55
STTK Shattuck Labs	N/A	27.59	27.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
BBOT BridgeBio Oncology Therapeutics	54.89%
KRRO Korro Bio	13.18%
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	1.90%
BBOT BridgeBio Oncology Therapeutics	24.40%
KRRO Korro Bio	4.80%
STTK Shattuck Labs	8.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	103.71 million	101.74 million	Not Optionable
BBOT BridgeBio Oncology Therapeutics	N/A	80.17 million	60.61 million	N/A
KRRO Korro Bio	70	14.73 million	14.02 million	No Data
STTK Shattuck Labs	100	100.36 million	91.54 million	Optionable

KRRO, AURA, STTK, and BBOT Headlines

Recent News About These Companies

Shattuck Labs, Inc. (NASDAQ:STTK) Receives Consensus Recommendation of "Buy" from Brokerages

4 hours ago | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Invests $1.99 Million in Shattuck Labs, Inc. $STTK

August 30 at 3:37 AM | marketbeat.com

356,528 Shares in Shattuck Labs, Inc. $STTK Bought by Deutsche Bank AG

August 28 at 3:37 AM | marketbeat.com

Shattuck Labs (NASDAQ:STTK) Upgraded at TD Cowen

August 27, 2026 | americanbankingnews.com

Raymond James Financial Upgrades Shattuck Labs (NASDAQ:STTK) to "Strong-Buy"

August 26, 2026 | marketbeat.com

Shattuck Labs (NASDAQ:STTK) Stock Rating Upgraded by TD Cowen

August 25, 2026 | marketbeat.com

Shattuck Labs (NASDAQ:STTK) Stock Price Up 5.5% - Here's What Happened

August 24, 2026 | marketbeat.com

S&G Foundation Makes New $3.02 Million Investment in Shattuck Labs, Inc. $STTK

August 23, 2026 | marketbeat.com

Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?

August 20, 2026 | zacks.com

Shattuck Labs (NASDAQ:STTK) Cut to Hold at Wall Street Zen

August 15, 2026 | marketbeat.com

Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade

August 13, 2026 | zacks.com

Q3 EPS Estimates for Shattuck Labs Raised by HC Wainwright

August 13, 2026 | marketbeat.com

Shattuck Labs Advances SL-325 Crohn’s Trial Toward a Key Value Milestone

August 12, 2026 | tipranks.com

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 11, 2026 | markets.businessinsider.com

Shattuck Labs Releases Q2 2026 10-Q Filing Highlighting Key Risk Factors and Share Count

August 11, 2026 | kalkinemedia.comK

HC Wainwright Cuts Shattuck Labs (NASDAQ:STTK) Price Target to $14.00

August 11, 2026 | marketbeat.com

Shattuck Labs (NASDAQ:STTK) Releases Earnings Results, Hits Expectations

August 11, 2026 | marketbeat.com

Shattuck Labs Reports Positive Phase 1 Data for SL-325 and Advances DR3 Pipeline with Phase 2b Crohn’s Study Planned for 2026

August 11, 2026 | quiverquant.comQ

Shattuck Labs, Inc. $STTK Stock Holdings Lifted by Renaissance Technologies LLC

August 8, 2026 | marketbeat.com

Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Rating of "Moderate Buy" by Brokerages

August 6, 2026 | marketbeat.com

Shattuck Labs (STTK) Projected to Release Earnings on Thursday

August 6, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KRRO, AURA, STTK, and BBOT Company Descriptions

Aura Biosciences NASDAQ:AURA

$7.11 -0.29 (-3.92%)

As of 12:27 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

BridgeBio Oncology Therapeutics NASDAQ:BBOT

$8.61 -0.13 (-1.49%)

As of 12:26 PM Eastern

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor is an affiliate of Cormorant, a leading life sciences focused investment firm with over $2 billion in assets under management as of December 31, 2022. Our Chairperson and Chief Executive Officer, Bihua Chen, founded Cormorant and is the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.

Korro Bio NASDAQ:KRRO

$12.52 -0.39 (-3.02%)

As of 12:19 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Shattuck Labs NASDAQ:STTK

$6.88 -0.16 (-2.27%)

As of 12:27 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KRRO, AURA, STTK, and BBOT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KRRO, AURA, STTK, and BBOT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KRRO, AURA, STTK, and BBOT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KRRO, AURA, STTK, and BBOT Company Descriptions

Aura Biosciences NASDAQ:AURA

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Korro Bio NASDAQ:KRRO

Shattuck Labs NASDAQ:STTK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KRRO, AURA, STTK, and BBOT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KRRO, AURA, STTK, and BBOT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KRRO, AURA, STTK, and BBOT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KRRO, AURA, STTK, and BBOT Company Descriptions

Aura Biosciences NASDAQ:AURA

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Korro Bio NASDAQ:KRRO

Shattuck Labs NASDAQ:STTK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools